EUCTR2009-015825-36-DE进行中（未招募）不适用
An Open Label Extension Study of the Efficacy of MORAb-003 in Subjects with Platinum-Sensitive Epithelial Ovarian Cancer in First Relapse
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Provision of informed consent
- •2. Subjects must currently be enrolled in and have met the inclusion/exclusion criteria of the MORAb-003-002 study
- •3. Subjects must have achieved a normalization of CA 125 levels and/or CR or PR (or stable disease and an investigator's assessment of a clinical benefit) after MORAb-003 in combination with standard chemotherapy and have not yet met criteria for disease progression and during participation on MORAb-003-002 study
- •4. Subjects must be currently receiving single-agent MORAb-003 maintenance therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects that discontinued the MORAb-003-002 study for any reason
研究者
相似试验
已完成
不适用
A clinical study to evaluate the efficacy of Macumaxcapsules in adultmale or female patients suffering from dry type Age related macular disorder.CTRI/2016/02/006676Sami Labs Limited40
进行中（未招募）
不适用
An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy Study - Open label extension study to verify long term safety of OxabactTM , the Phoenix II studyprimary hyperoxaluriaMedDRA version: 9.1Level: LLTClassification code 10020703Term: HyperoxaluriaEUCTR2007-006187-30-DEOxThera, Inc.42
进行中（未招募）
1 期
An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy Study - Open label extension study to verify long term safety of OxabactTM , the Phoenix II studyprimary hyperoxaluriaMedDRA version: 9.1 Level: LLT Classification code 10020703 Term: HyperoxaluriaEUCTR2007-006187-30-GBOxThera, Inc.
尚未招募
3 期
An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy StudyPrimary Hyperoxaluria (PH)1002160510038430NL-OMON31883OxThera Inc.4
进行中（未招募）
1 期
An Open-label (OL) Extension Study evaluating the Long-Term Safety of OxabactTM in Subjects with Primary Hyperoxaluria (PH) who participated in the Double-Blind (DB) Efficacy Study - Open label extension study to verify long term safety of OxabactTM , the Phoenix II studyEUCTR2007-006187-30-FROxThera, Inc.